UnknownNot Applicable

Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma

South Korea30 participantsStarted 2022-10-06

Plain-language summary

This prospective study aims to perform intra-individual comparison of the image quality between ultra-low-dose whole-body CT with deep learning reconstruction and conventional low-dose whole-body CT with iterative reconstruction in patients with suspected multiple myeloma.

Who can participate

Age range19 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * signed informed consent * patients with suspected multiple myeloma and scheduled for noncontrast-enhanced low-dose whole-body CT * patients who have no previous history of chemotherapy for multiple myeloma Exclusion Criteria: * patients who do not agree to the protocol * non-Korean patients * pregnancy

What they're measuring

Contrast-to-noise ratio

Timeframe: 3 months after the CT scan

Trial details

NCT IDNCT05577884

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-31

Contact for this trial

Hee-Dong Chae, MD

82-2-2072-4209 hdchae02@gmail.com

View on ClinicalTrials.gov More Multiple Myeloma trials